#USA #San Francisco #Investor Alert #Hagens Berman #PROCEPT BioRobotics

Hagens Berman Alerts Investors of Class Action Opportunity

Investors who have sustained significant losses in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) should take heed of a recent alert from Hagens Berman Sobol Shapiro LLP. This prestigious firm has informed shareholders that a class action lawsuit has been filed against the company, primarily due to its tremendous sales underperformance and issues related to excess customer inventory levels.

The lawsuit, which targets individuals who purchased PROCEPT common stock between February 28, 2024, and February 25, 2026, claims that crucial information was withheld from investors concerning the company's single-use handpiece sales, a pivotal part of its patented Aquablation therapy aimed at treating an enlarged prostate. According to the allegations, the company's misleading communication practices regarding sales growth have caused significant financial damage to its investors.

The Heart of the Matter

The core of the complaint rests on the assertion that PROCEPT incentivized customers to place bulk orders, surpassing their actual needs. This tactic was intended to artificially inflate reported unit sales and revenue figures while pushing sales into the current quarter at the expense of future periods. Consequently, as investors remained unaware of these practices, they were misled into believing the company's growth was on an upward trajectory.

Hagens Berman highlights specific events that unfolded during the class period. Notably, on August 6, 2025, PROCEPT disclosed its Q2 2025 financial results. The report revealed a sharp decline in handpiece sales that fell significantly short of market expectations. This initial disclosure triggered a downward shift in PROCEPT’s stock price.

Subsequent earnings reports continued to dispel any optimism regarding the company’s performance. The Q3 2025 results, released on November 4, 2025, also missed projections for handpiece sales. Management even adjusted its annual sales guidance downward, acknowledging that the company failed to manage customer inventory, resulting in customers holding onto excessive stocks.

By the time the company revealed its Q4 2025 results on February 25, 2026, it became clear that total excess inventory of handpieces was alarmingly high. Management disclosed that U.S. handpiece sales had dramatically outpaced procedure quantities, indicating severe mismanagement of sales projections and customer inventories.

Consequently, the stock price plummeted, showcasing how misinformation and lack of transparency can severely impact shareholder value. The lawsuit also questions whether PROCEPT strategically pulled sales forward to meet quarterly expectations, calling into account the integrity of the company’s financial communications.

Immediate Actions for Affected Investors

The firm urges all affected investors who suffered substantial losses to act promptly by submitting their claims. Those who possess additional knowledge pertinent to the ongoing investigation are encouraged to contact Hagens Berman directly. This situation underscores the importance of corporate transparency, particularly in the healthcare industry, where stock prices can significantly affect investments.

Support for Whistleblowers

In relation to this case, Hagens Berman also emphasizes the importance of whistleblower contributions. Individuals with non-public information regarding PROCEPT are encouraged to consider participating in the investigation or utilizing the SEC Whistleblower program, which offers rewards for original information that leads to successful enforcement actions.

About Hagens Berman

Hagens Berman is a leading global plaintiffs’ rights law firm. The firm has a strong track record in complex litigation, representing investors, whistleblowers, and consumers against corporate wrongdoing. With more than $2.9 billion secured in settlements, Hagens Berman has cemented its status as a formidable advocate for those harmed by corporate negligence.

For more information about the PROCEPT case or the firm's investigations, please visit their website or contact them directly.